MG 1102

Drug Profile

MG 1102

Alternative Names: Greenstatin; MG1102; Recombinant anti-angiogenic protein - Green Cross; Recombinant human apolipoprotein (a) Kringle V; rhLK8

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Green Cross
  • Class Antineoplastics; Apolipoprotein therapeutics; Gene therapies; Recombinant proteins
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in South Korea (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Infusion)
  • 12 Mar 2013 Green Cross completes enrolment in its phase I trial for Solid tumours in USA & South Korea (NCT01809912)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top